Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching
7+ hour, 15+ min ago (374+ words) The Clinical Trial Vanguard Meant Launches LegitScript-Certified GLP-1 Telehealth Platform with Coaching The GLP-1 telehealth market has expanded fast enough that certification has become a differentiator, and Meant is leaning on that directly. The platform launched this week with LegitScript…...
The AI Validation Gap: Decision Support Tools Are Outrunning Their Own Evidence
6+ hour, 26+ min ago (679+ words) The Clinical Trial Vanguard The AI Validation Gap: Decision Support Tools Are Outrunning Their Own Evidence Three developments have converged in the past eighteen months that the clinical operations community has not yet named as a single phenomenon: AI decision…...
Aizen Raises Up to $100M Per Target in San Diego Biotech Peptide Deal
7+ hour, 17+ min ago (248+ words) The Clinical Trial Vanguard Aizen Raises Up to $100M Per Target in San Diego Biotech Peptide Deal A seed-stage company that raised $13 million less than two years ago just locked in a deal worth up to $100 million per nominated target, and…...
Skye Bioscience Acquires Redx Pharma, Exits Obesity for Fibrosis Focus
7+ hour, 16+ min ago (217+ words) The Clinical Trial Vanguard Skye Bioscience Acquires Redx Pharma, Exits Obesity for Fibrosis Focus Skye Bioscience is walking away from obesity entirely. The company announced on August 14, 2026, that it has signed a transaction agreement to acquire Redx Pharma Limited and…...
Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination
7+ hour, 18+ min ago (479+ words) The Clinical Trial Vanguard Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination An 86% objective response rate in a Phase 1 trial gets attention in any context, but the setting here sharpens the stakes considerably: LYMPHIR (denileukin diftitox-cxdl), approved in August…...
LSD Just Beat Phase 3 Twice. Now Comes the Hard Part.
20+ hour, 47+ min ago (620+ words) The Clinical Trial Vanguard LSD Just Beat Phase 3 Twice. Now Comes the Hard Part. The field keeps treating psychedelic clinical validation as a future-tense problem. After Definium Therapeutics’ DT120 cleared Phase 3 in both major depressive disorder and generalized anxiety disorder, it…...
AI Clinical Decision Support Is Outrunning Its Own Evidence Base: What Trial Operators Need to Know Now
1+ day, 6+ hour ago (489+ words) The Clinical Trial Vanguard AI Clinical Decision Support Is Outrunning Its Own Evidence Base: What Trial Operators Need to Know Now Seventy-one percent of U.S. hospitals were running predictive AI integrated into their electronic health records by 2024, according to ONC’s Hospital…...
AI Clinical Decision Support Is Everywhere. The Evidence Base Is Not.
2+ day, 6+ hour ago (918+ words) The Clinical Trial Vanguard AI Clinical Decision Support Is Everywhere. The Evidence Base Is Not. Imagine a site coordinator at a large academic medical center pulling up a patient’s chart in the middle of a Phase 3 oncology trial. Before she…...
Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028
2+ day, 7+ hour ago (421+ words) The Clinical Trial Vanguard Nektar Raises Cash to Fund Rezpegaldesleukin Phase 3 Trials Through 2028 Nektar Therapeutics ended June with $1.02 billion in cash and investments, a figure that jumped from $245.8 million at year-end 2025 largely on the back of a $373.8 million equity offering…...
Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 EGFR Exon 20 Trial
2+ day, 7+ hour ago (450+ words) The Clinical Trial Vanguard Zipalertinib Plus Chemotherapy Meets Primary Endpoint in Phase 3 EGFR Exon 20 Trial EGFR exon 20 insertion mutations account for roughly 2–3% of all NSCLC diagnoses, a slice small enough that pivotal trial recruitment is brutally slow yet large enough…...